Three Phase II studies investigating bortezomib, a proteosome inhibitor that blocks the NF-κB pathway, as a single agent or in combination with ET, did not elicit an objective tumour response in metastatic breast cancer patients [62–64]. Here, NFKB1 is linked to neoplasm.